This conclusion is also applicable for samples with positive TRPC7 mRNA abundancy (89.0%), meaning that in any case of positive signal for TRPC3 or TRPC7 expression in a given tumor, the tumor cells frequently possesses the prominent mTOR pathway activating mutation. This evidence concerns the gene TRPC3 and neoplasm.